Nabsys at ASHG 2026

Oct 20–24, 2026 Montréal, Canada ~7.5k attendees Website

Nabsys brings 4 presentations to ASHG 2026 in Montréal, and exhibits at Booth 501. Its program at this meeting centres on electronic genome mapping, CRISPR/Cas9 assay development, and structural variants including repeat expansions. Its presentations cover CRISPR-assisted mapping of Robertsonian translocations and FSHD, repeat-expansion assays, and LINE-1 ORF2p activity.

Organization

ASHG 2026 Attendance

Nabsys

Dallas, Texas

2 Application Scientist · 1 Software Product Manager · 1 Principal Scientist

nabsys.com|LinkedIn

Subsidiary

Nabsys provides electronic genome mapping tools for research laboratories. Its OhmX Platform combines an analyzer, consumables, and software for structural-variant analysis.

Nabsys began a multi-year research collaboration with Indiana University School of Medicine on hematologic malignancy applications for its OhmX platform.

›

Nabsys began a multi-year research collaboration with Indiana University School of Medicine on hematologic malignancy applications for its OhmX platform.

2026-07 · source

Nabsys signed a lease for a new 30,000-square-foot headquarters in Providence, signaling company growth and expansion plans.

2026-07 · source

Nabsys appointed Alka Chaubey as chief medical and genomics officer, adding a genome-mapping veteran to its leadership team.

2026-07 · source

Source: company newsroom

Raised $38M expanded equity round (Nov 2022)

›

Included an additional $13M from Hitachi High-Tech as part of the expanded round. · 2022-11-09

“announced today that it has received an additional $13 million from Hitachi High-Tech as part of an expanded equity round now totaling $38 million.”

Source: funding announcement

Currently hiring: 7 open roles